Boston Scientific (NYSE: BSX) reported Q2 EPS of $0.86, $0.03 better than the analyst estimate of $0.83. Revenue for the quarter came in at $5.44 billion versus the consensus estimate of $5.37 billion.

GUIDANCE:

Boston Scientific sees FY2026 EPS of $3.28-$3.32, versus the consensus of $3.36.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.